1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-oncology Biopharmaceuticals Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Biologics
1.2.3 Biosimilars
1.3 Market by Application
1.3.1 Global Non-oncology Biopharmaceuticals Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-oncology Biopharmaceuticals Market Perspective (2017-2028)
2.2 Non-oncology Biopharmaceuticals Growth Trends by Region
2.2.1 Non-oncology Biopharmaceuticals Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-oncology Biopharmaceuticals Historic Market Size by Region (2017-2022)
2.2.3 Non-oncology Biopharmaceuticals Forecasted Market Size by Region (2023-2028)
2.3 Non-oncology Biopharmaceuticals Market Dynamics
2.3.1 Non-oncology Biopharmaceuticals Industry Trends
2.3.2 Non-oncology Biopharmaceuticals Market Drivers
2.3.3 Non-oncology Biopharmaceuticals Market Challenges
2.3.4 Non-oncology Biopharmaceuticals Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue
3.1.1 Global Top Non-oncology Biopharmaceuticals Players by Revenue (2017-2022)
3.1.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Players (2017-2022)
3.2 Global Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-oncology Biopharmaceuticals Revenue
3.4 Global Non-oncology Biopharmaceuticals Market Concentration Ratio
3.4.1 Global Non-oncology Biopharmaceuticals Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-oncology Biopharmaceuticals Revenue in 2021
3.5 Non-oncology Biopharmaceuticals Key Players Head office and Area Served
3.6 Key Players Non-oncology Biopharmaceuticals Product Solution and Service
3.7 Date of Enter into Non-oncology Biopharmaceuticals Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-oncology Biopharmaceuticals Breakdown Data by Type
4.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Type (2017-2022)
4.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Type (2023-2028)
5 Non-oncology Biopharmaceuticals Breakdown Data by Application
5.1 Global Non-oncology Biopharmaceuticals Historic Market Size by Application (2017-2022)
5.2 Global Non-oncology Biopharmaceuticals Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-oncology Biopharmaceuticals Market Size (2017-2028)
6.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Non-oncology Biopharmaceuticals Market Size (2017-2028)
7.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size (2017-2028)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Non-oncology Biopharmaceuticals Market Size (2017-2028)
9.2 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
9.3 Latin America Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size (2017-2028)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2017-2022)
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Non-oncology Biopharmaceuticals Introduction
11.1.4 Roche Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Non-oncology Biopharmaceuticals Introduction
11.2.4 Sanofi Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.2.5 Sanofi Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Introduction
11.3.4 Johnson & Johnson Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.3.5 Johnson & Johnson Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Non-oncology Biopharmaceuticals Introduction
11.4.4 Pfizer Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.4.5 Pfizer Recent Development
11.5 Novo Nordisk
11.5.1 Novo Nordisk Company Detail
11.5.2 Novo Nordisk Business Overview
11.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Introduction
11.5.4 Novo Nordisk Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.5.5 Novo Nordisk Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Non-oncology Biopharmaceuticals Introduction
11.6.4 Novartis Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.6.5 Novartis Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Non-oncology Biopharmaceuticals Introduction
11.7.4 Merck Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.7.5 Merck Recent Development
11.8 Teva
11.8.1 Teva Company Detail
11.8.2 Teva Business Overview
11.8.3 Teva Non-oncology Biopharmaceuticals Introduction
11.8.4 Teva Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.8.5 Teva Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Detail
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Non-oncology Biopharmaceuticals Introduction
11.9.4 Eli Lilly Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.9.5 Eli Lilly Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Detail
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Introduction
11.10.4 Bristol-Myers Squibb Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.10.5 Bristol-Myers Squibb Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Detail
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Introduction
11.11.4 GlaxoSmithKline Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.11.5 GlaxoSmithKline Recent Development
11.12 UCB Pharma
11.12.1 UCB Pharma Company Detail
11.12.2 UCB Pharma Business Overview
11.12.3 UCB Pharma Non-oncology Biopharmaceuticals Introduction
11.12.4 UCB Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.12.5 UCB Pharma Recent Development
11.13 Amgen
11.13.1 Amgen Company Detail
11.13.2 Amgen Business Overview
11.13.3 Amgen Non-oncology Biopharmaceuticals Introduction
11.13.4 Amgen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.13.5 Amgen Recent Development
11.14 AbbVie
11.14.1 AbbVie Company Detail
11.14.2 AbbVie Business Overview
11.14.3 AbbVie Non-oncology Biopharmaceuticals Introduction
11.14.4 AbbVie Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.14.5 AbbVie Recent Development
11.15 Takeda
11.15.1 Takeda Company Detail
11.15.2 Takeda Business Overview
11.15.3 Takeda Non-oncology Biopharmaceuticals Introduction
11.15.4 Takeda Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.15.5 Takeda Recent Development
11.16 AstraZeneca
11.16.1 AstraZeneca Company Detail
11.16.2 AstraZeneca Business Overview
11.16.3 AstraZeneca Non-oncology Biopharmaceuticals Introduction
11.16.4 AstraZeneca Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.16.5 AstraZeneca Recent Development
11.17 Mylan
11.17.1 Mylan Company Detail
11.17.2 Mylan Business Overview
11.17.3 Mylan Non-oncology Biopharmaceuticals Introduction
11.17.4 Mylan Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.17.5 Mylan Recent Development
11.18 LEO Pharma
11.18.1 LEO Pharma Company Detail
11.18.2 LEO Pharma Business Overview
11.18.3 LEO Pharma Non-oncology Biopharmaceuticals Introduction
11.18.4 LEO Pharma Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.18.5 LEO Pharma Recent Development
11.19 Boehringer Ingelheim
11.19.1 Boehringer Ingelheim Company Detail
11.19.2 Boehringer Ingelheim Business Overview
11.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Introduction
11.19.4 Boehringer Ingelheim Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.19.5 Boehringer Ingelheim Recent Development
11.20 Alexion Pharmaceuticals
11.20.1 Alexion Pharmaceuticals Company Detail
11.20.2 Alexion Pharmaceuticals Business Overview
11.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Introduction
11.20.4 Alexion Pharmaceuticals Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.20.5 Alexion Pharmaceuticals Recent Development
11.21 Elusys Therapeutics
11.21.1 Elusys Therapeutics Company Detail
11.21.2 Elusys Therapeutics Business Overview
11.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Introduction
11.21.4 Elusys Therapeutics Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.21.5 Elusys Therapeutics Recent Development
11.22 Swedish Orphan Biovitrum
11.22.1 Swedish Orphan Biovitrum Company Detail
11.22.2 Swedish Orphan Biovitrum Business Overview
11.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Introduction
11.22.4 Swedish Orphan Biovitrum Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.22.5 Swedish Orphan Biovitrum Recent Development
11.23 Biogen
11.23.1 Biogen Company Detail
11.23.2 Biogen Business Overview
11.23.3 Biogen Non-oncology Biopharmaceuticals Introduction
11.23.4 Biogen Revenue in Non-oncology Biopharmaceuticals Business (2017-2022)
11.23.5 Biogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
